CD274 and nasopharyngeal carcinoma: Exploration of immunotherapy with PD-1/PDL1 checkpoint blockade in RM-NPC patients beyond first-line treatment has been reported in clinical trials with relatively small samples [13–15], with all patients having received monotherapy with pembrolizumab, nivolumab, or camrelizumab.